Andrea Taddei
About Andrea Taddei
Andrea Taddei is the Director of Drug Discovery at BenevolentAI, with extensive experience in molecular biology and drug discovery.
Title
Andrea Taddei holds the position of Director Drug Discovery at BenevolentAI.
Company
Andrea Taddei is currently working at BenevolentAI, where he has served in various roles such as Director Drug Discovery, Senior Principal Scientist, Drug Discovery Team Lead, and Drug Discovery - Exploratory Scientist. He has been with BenevolentAI since 2018, contributing his expertise to various facets of drug discovery.
Previous Roles
Before his tenure at BenevolentAI, Andrea Taddei worked at The Francis Crick Institute as a Postdoctoral Research Fellow for six years. Prior to that, he was at IFOM, having held roles such as Postdoc, PhD Student, and Research Fellow from 2004 to 2011 in Milan, Italy. His extensive background also includes research in endothelial junctions and vascular stabilization.
Education and Expertise
Andrea Taddei earned his Doctor of Philosophy (PhD) in Molecular Medicine from the European School of Molecular Medicine (SEMM) - IFOM, Milan, Italy, from 2005 to 2009. He also holds a Master's degree in Medical Biotechnology from the Università di Bologna, completed between 1999 and 2004. With over 12 years of academic research experience in cellular and molecular biology, his expertise spans endothelial junctions, vascular stabilization, gene expression regulation, epigenetics, and in vivo models of vascular development.
Achievements and Collaboration
Andrea Taddei leads the biology aspect of BenevolentAI's collaboration with AstraZeneca focusing on chronic kidney disease. He has overseen the development of strategies for prioritizing drug targets with the highest potential. His role includes managing multidisciplinary teams from AI-powered target identification to hypothesis validation and candidate selection for chemistry optimization.